Stock Groups

FDA ruling on Pfizer’s COVID jab for kids could come in November


© Reuters. FILE PHOTO – This illustration shot taken March 19, 2021, shows an vial that has been labelled with Pfizer BioNTech’s coronavirus (COVID-19). REUTERS/Dado Ruvic/Illustration

WASHINGTON (Reuters) – U.S. health regulators’ decision on whether to approve Pfizer (NYSE:) and BioNTech’s COVID-19 vaccine for children ages 5 to 11 could spill over into November if needed, the nation’s top u.s. infectious disease official said on Wednesday.

When Dr. Anthony Fauci was asked about Wall Street Journal reports that an expanded approval might not be forthcoming next month, he said that the Food and Drug Administration is working quickly and that “if that goes into November that’s because that’s what it’s needed.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are provided by market makers. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.


Banner 3